76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
NeoGenomics Inc
Closed
7.41 4.07
Overview
Share price change
24h
Min
7.11
Max
7.42
Income | -11M -26M |
|---|---|
Sales | -4M 168M |
EPS | -0.204 |
Profit margin | -15.427 |
Employees | 2,200 |
EBITDA | -10M -6.3M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +78.73% upside |
Next Earnings | 28 Jul 2025 |
|---|
Market Cap | -360M 923M |
|---|---|
Previous open | 3.34 |
Previous close | 7.41 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
NeoGenomics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
NeoGenomics Inc Forecast
Price Target
By TipRanks
78.73% upside
12 Months Forecast
Average 13.19 USD 78.73%
High 26 USD
Low 8.5 USD
Based on 12 Wall Street analysts offering 12 month price targets forNeoGenomics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
